1. Introduction {#sec1-ijms-17-01090}
===============

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death for all devastating human malignancies \[[@B1-ijms-17-01090],[@B2-ijms-17-01090],[@B3-ijms-17-01090]\]. Surgical resection is still the only potentially curative therapeutic option \[[@B3-ijms-17-01090]\]. Unfortunately, upon the diagnosis of PDAC, the majority of patients have an advanced stage of disease and cannot be cured by resection \[[@B4-ijms-17-01090]\]. Even if a potentially curative resection can be performed, the median survival is shorter than 20 months, and the rate of five-year overall survival is less than 20% \[[@B2-ijms-17-01090],[@B4-ijms-17-01090],[@B5-ijms-17-01090],[@B6-ijms-17-01090]\]. Due to the frequency of local recurrence and distant metastases after resection, adjuvant therapy is necessary to decrease the risk of locoregional recurrence and distant metastases \[[@B3-ijms-17-01090],[@B4-ijms-17-01090],[@B5-ijms-17-01090],[@B7-ijms-17-01090]\]. However, the significance of different adjuvant strategies in pancreatic cancer are inconclusively and insufficiently reported in previous studies \[[@B8-ijms-17-01090],[@B9-ijms-17-01090],[@B10-ijms-17-01090]\]. Multiple prognostic factors for PDAC (pancreatic duct adenocarcinoma) have been thoroughly studied and include gender, age, size and location of the tumor, tumor stage, lymph node metastasis status, tumor grade, and serum carbohydrate antigen 19-9 level, but the sensitivities of these prognostic factors are limited in the absence of carcinoma-associated proteins expression profiles \[[@B4-ijms-17-01090]\].

Human epidermal growth factor receptor (EGFR (epidermal growth factor receptor) or HER1) is a member of the transmembrane tyrosine kinase receptor family and has been shown to be involved in the regulation of growth, differentiation and proliferation in solid tumors \[[@B11-ijms-17-01090],[@B12-ijms-17-01090],[@B13-ijms-17-01090]\]. Overexpression of EGFR has been discovered in a wide variety of solid tumors, including breast, prostate, colon and non-small cell lung neoplasms \[[@B11-ijms-17-01090],[@B12-ijms-17-01090],[@B13-ijms-17-01090],[@B14-ijms-17-01090]\]. For pancreatic adenocarcinoma, EGFR expression levels reported in different series have ranged from 25% to 90%, and EGFR expression has been shown to be associated with advanced stage, metastatic disease, and poor differentiation and survival \[[@B6-ijms-17-01090],[@B7-ijms-17-01090],[@B13-ijms-17-01090],[@B15-ijms-17-01090],[@B16-ijms-17-01090],[@B17-ijms-17-01090]\]. Besides, EGFR and its downstream signaling effectors have vital roles in the development and progression of PDAC \[[@B16-ijms-17-01090],[@B18-ijms-17-01090],[@B19-ijms-17-01090]\]. However, the significance of EGFR expression in terms of clinical outcomes is not well defined.

The current study investigated the association between EGFR expression and pancreatic cancer outcome in an East Asian population. We retrospectively examined the EGFR expression profiles of 357 resected PDAC specimens and analyzed the association of EGFR expression with prognosis in the overall population as well as the subgroups.

2. Results {#sec2-ijms-17-01090}
==========

2.1. Patient Characteristics According to EGFR (Epidermal Growth Factor Receptor) Expression {#sec2dot1-ijms-17-01090}
--------------------------------------------------------------------------------------------

The clinicopathologic characteristics of 357 patients pathologically confirmed with PDAC were reviewed. EGFR expression was determined immunohistochemically on the surface and in the cytoplasm of cancer cells within resected tissues, but none was observed in the surrounding stroma ([Figure 1](#ijms-17-01090-f001){ref-type="fig"}). Membranous or cytoplasmic EGFR expression was detected in 54.6% (195 of 357) of the examined tissue specimens. One hundred three specimens (44.6%) of the 231 younger patients (age ≤ 65 years) and 59 specimens (45.2%) of the 126 elder patients (age \> 65 years) were identified as EGFR-positive. The positive rates of EGFR expression were 48.3% (99/205) for females and 41.5% (63 of 152) for males. More detailed information of the patients' characteristics and EGFR expression profiles are shown in [Table 1](#ijms-17-01090-t001){ref-type="table"}. EGFR expression was not significantly associated with tumor size or location (*p* = 0.937 and 0.705, respectively) or CA19-9 level (*p* = 0.435). Furthermore, EGFR expression was not significantly correlated with metastasis to nerves, blood vessels and lymph nodes (*p* = 0.180, 0.931 and 0.736, respectively) ([Table 1](#ijms-17-01090-t001){ref-type="table"}). EGFR expression in the resected tissues was not correlated with tumor proliferation (*p* = 0.154 for Ki67 analysis) or tumor stages (*p* = 0.473); however, there was a correlation with differentiation (*p* = 0.015) ([Table 1](#ijms-17-01090-t001){ref-type="table"}).

2.2. EGFR Status Was Not Correlated with Overall Survival after Surgical Resection {#sec2dot2-ijms-17-01090}
----------------------------------------------------------------------------------

The median survival of the overall population was 13.9 months. The associations of the clinical outcomes with demographic and prognostic factors were also investigated. Earlier tumor stages, non-lymph metastasis and EGFR negative expression were significantly related to a longer progression free survival (PFS) (*p* = 0.006, *p* = 0.001 and *p* = 0.040) ([Table 1](#ijms-17-01090-t001){ref-type="table"}). The univariate analysis of median overall survival (OS) revealed that those patients: (a) with a lower CA19-9 level (≤37 U/mL), with a smaller tumor size (≤3 cm), with poorer differentiation and earlier stage; (b) with no lymph node or vascular invasion; and (c) treated with chemotherapy or radiotherapy showed a significantly longer survival than those with a different status (each *p*-value was \<0.05) ([Table 2](#ijms-17-01090-t002){ref-type="table"}). The remaining parameters were negatively associated with prognosis. Although EGFR expression was significantly associated with median PFS (*p* = 0.040), patients negative for EGFR expression were less likely to have a favorable prognosis than those positive for EGFR expression (median OS: 15.0 vs. 13.1 months, Hazard ratios (HR) = 1.07, *p* = 0.574), and this result is different from those of previous similar studies \[[@B6-ijms-17-01090],[@B16-ijms-17-01090],[@B17-ijms-17-01090]\].

2.3. EGFR Status Was Not Correlated with Overall Survival after Surgical Resection Patients {#sec2dot3-ijms-17-01090}
-------------------------------------------------------------------------------------------

CA19-9 level, tumor size, differentiation, stage, and vessel or lymph invasion, the potential prognostic factors, were significantly correlated with median OS ([Table 2](#ijms-17-01090-t002){ref-type="table"}); however, no correlation was observed between EGFR expression and OS ([Table 2](#ijms-17-01090-t002){ref-type="table"} and [Figure 1](#ijms-17-01090-f001){ref-type="fig"}). The associations of each prognostic parameter with survival were compared between the EGFR-negative and EGFR-positive subgroups. The significant association between CA19-9 level and favorable prognosis, as observed in the overall population, was only detectable in the EGFR-negative subgroup (HR \> 1.0, *p* \< 0.050 for both univariate analysis and multivariate analysis); this result was also found in the associations of negative nerve invasion and negative vessel invasion with favorable prognosis. In contrast, tumor size was the only factor significantly correlated with OS in the EGFR-positive subgroup (HR \> 2.0, *p* \< 0.001 for both univariate analysis and multivariate analysis) ([Table 3](#ijms-17-01090-t003){ref-type="table"}), and larger tumor size clearly had the highest HR (3.27) of all the prognostic factors evaluated. Lymph node metastasis had strong prognostic implications in both the EGFR-negative and EGFR-positive subgroups (HR \> 1.0, *p* \< 0.050 for both univariate analysis and multivariate analysis).

Furthermore, we investigated the prognostic value of postoperative adjuvant therapy in both EGFR subgroups. Chemotherapy was the only significant factor significantly associated with survival in the EGFR-positive subgroup, and the significance levels obtained in the univariate and multivariate analyses were comparable; however, radiotherapy demonstrated only a slight advantage in the EGFR-positive subgroup using the univariate analysis. In contrast to chemotherapy, radiotherapy showed a significant survival benefit in the EGFR-negative subgroup in both the univariate and multivariate analyses, and only a slight advantage was found in the univariate analysis (*p =* 0.055) in the EGFR-positive subgroup. Likewise, age, gender and tumor location were parameters all weakly associated with survival ([Table 3](#ijms-17-01090-t003){ref-type="table"}). Additionally, stratified by EGFR expression, patients with smaller size, non-lymph metastasis and accepted radiotherapy showed longer median PFS in the EGFR positive group (*p* \< 0.05); however, patients with non-nerve invasion were found to have a better PFS in the EGFR negative group (*p =* 0.022) ([Supplementary Table S1](#app1-ijms-17-01090){ref-type="app"}).

2.4. EGFR Status Was Not Correlated with Overall Survival after Surgical Resection Patients {#sec2dot4-ijms-17-01090}
-------------------------------------------------------------------------------------------

The Kaplan--Meier curves revealed a similar prognostic value of EGFR expression in terms of short-term survival. The OS curves stratified by positive and negative EGFR expression were shown in [Figure 2](#ijms-17-01090-f002){ref-type="fig"} and suggested that EGFR expression in resected pancreatic cancer was not correlated with survival; this result was in accordance with the statistical analysis findings presented in [Table 2](#ijms-17-01090-t002){ref-type="table"}. The Kaplan--Meier curve also indicated that patients with negative EGFR expression had a longer median PFS than others with positive EGFR expression within approximately 30 months ([Supplementary Figure S1](#app1-ijms-17-01090){ref-type="app"}). The statistical analysis showed a negative correlation between chemotherapy treatment and EGFR expression ([Table 1](#ijms-17-01090-t001){ref-type="table"}). However, undergoing chemotherapy or radiotherapy was independently and highly significantly correlated with favorable outcomes ([Table 2](#ijms-17-01090-t002){ref-type="table"}).

The prognosis of patients treated with adjuvant therapy was analyzed in both the EGFR-positive (EGFR (+)) and EGFR-negative (EGFR (−)) subgroups ([Table 3](#ijms-17-01090-t003){ref-type="table"}). To further determine the correlation between postoperative chemotherapy (chemo) and EGFR expression, all patients with available final survival data were divided into four Groups: EGFR (+) and chemo; EGFR (+) and no chemo; EGFR (−) and chemo; EGFR (−) and no chemo. The investigation of OS in these Groups showed a benefit of postoperative chemotherapy in both the EGFR (+) and EGFR (−) subgroups. Particularly, EGFR-positive patients who underwent chemotherapy showed increased survival compared to those who without chemotherapy; however, this difference was less obvious in the EGFR-negative subgroup ([Figure 3](#ijms-17-01090-f003){ref-type="fig"}). Similarly, patients who received radiotherapy following radical resection showed increased survival compared with those without, but this difference was not statistically insignificant in the EGFR (+) and EGFR (−) subgroups ([Figure 4](#ijms-17-01090-f004){ref-type="fig"}). However, postoperative chemotherapy was effective in preventing the tumor progression among the EGFR negative patients, which was not detected in the EGFR positive cases. Moreover, this effect was not detected in the postoperative radiotherapy ([Supplementary Figure S2](#app1-ijms-17-01090){ref-type="app"}).

3. Discussion {#sec3-ijms-17-01090}
=============

Although radical resection can be curative, the median OS of PDAC patients following radical resection is less than 20 months. Early metastasis and recurrence are the main reasons for the dismal prognosis of this disease even after curative resection. Distinguishing patients who are at high risk recurrence and distant organ metastasis after surgery is crucial for an improved survival since conventional factors are not completely conclusive and potent. Therefore, the prognostic ability of EGFR in pancreatic cancer is an ongoing topic of discussion.

We conducted a retrospective study of EGFR expression in postoperative patients and investigated its correlation with the clinical outcomes of PDAC patients. To the best of our knowledge, this study is the largest population-based study to evaluate EGFR expression as a potential prognostic marker in East Asian patients with resectable PDAC. Consistent with some recent studies, we showed that the rate of EGFR expression was 45.4% among the pancreatic cancer patients, as tested by a total of 357 patients with pancreatic carcinoma \[[@B20-ijms-17-01090]\]. We revealed that EGFR expression's slight correlations with age, gender, CA19-9, and tumor site, size, stage, and grade. Additionally, the EGFR expression can serve as an independent marker indicative of tumor invasion and metastasis Radiotherapy was found to be a confounder of the distribution of EGFR express, and this result should be verified by future studies.

Previous reports showed that EGFR over-expression may predict shorter survival in multiple solid tumors, including pancreatic tumors \[[@B6-ijms-17-01090],[@B14-ijms-17-01090],[@B17-ijms-17-01090]\]. A prior study found a significant correlation between high EGFR expression and shorter overall survival (*p* = 0.014) in 88 surgical patients by measuring mRNA levels in paraffin-embedded (FFPE) tissues \[[@B17-ijms-17-01090]\]. In addition, the expression of EGFR was reported in conjunction with insulinlike growth factor 1 receptor (IGF-1R) to predict poor survival in pancreatic ductal adenocarcinoma \[[@B21-ijms-17-01090]\]. However, we were unable to detect a significant difference in OS between the EGFR-positive and EGFR-negative subgroups (OS: 15.0 vs. 13.1 months, *p* = 0.98). Similar studies also reported the deficiency of correlation between EGFR expression and overall survival \[[@B22-ijms-17-01090],[@B23-ijms-17-01090]\]. These conflicting results may be partially due to the differences in the patient populations between the previous study and our study, including ethnic differences, various ratios of resectable to advanced patients, and inclusion of multiple types of pancreatic cancer. Additionally, differences in the laboratory methodologies used when analyzing overall survival could also have contributed to the conflicting results, and these findings are consistent with a previous systematic meta-analysis \[[@B24-ijms-17-01090]\].

The high rate of recurrence observed indicated the enormous difficulties to eliminate microscopic systemic spread by surgical resection alone; thus, adjuvant therapies must be investigated to improve postoperative survival in PDAC patients. Gemcitabine-based and 5-FU-based adjuvant chemotherapies have been widely accepted to be capable of increasing OS in patients with resected pancreatic cancer; however, the optimization between therapeutic regimens is controversial \[[@B4-ijms-17-01090],[@B8-ijms-17-01090],[@B25-ijms-17-01090]\]. The high rate of recurrence suggests that adjuvant therapies are necessary for even R0 resected disease to improve survival outcomes in these patients. Although we repeatedly stressed the significance of adjuvant therapy, 99 patients had persisted to refuse any adjuvant therapy. The survival analysis of this study showed that both adjuvant chemotherapy and radiotherapy following resection have significant survival benefits in PDAC patients ([Table 2](#ijms-17-01090-t002){ref-type="table"}). Additionally, our results suggest that EGFR-positive patients are more likely to benefit from adjuvant chemotherapy than EGFR-negative patients, indicating greater sensitivity to chemotherapy in EGFR-positive patients. Conversely, adjuvant radiotherapy only improved survival in the EGFR-negative subgroup, and this finding requires confirmation by prospective randomized clinical trials. The approaches to enhance sensitivity to chemotherapy and radiotherapy are complex, and particularly relevant for signaling pathways involved in metabolism and apoptosis \[[@B9-ijms-17-01090],[@B26-ijms-17-01090]\]. As far as we know, there is no precise mechanism, related to EGFR expression regulating the chemotherapy effects, has been reported in pancreatic cancer. According to a recent study, Kim et al. found that EGFR expression had better overall survival in the gastric cancer patients who received adjuvant chemotherapy \[[@B27-ijms-17-01090]\]. Additional evidences has also been suggesting that cytotoxic chemotherapy is more effective among patients with high EGFR expression than in those with low EGFR expression in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC), respectively \[[@B28-ijms-17-01090],[@B29-ijms-17-01090]\]. The prognostic and predictive roles of EGFR expression in pancreatic cancer remain controversial.

In pancreatic cancer, overexpressed EGFR regulates downstream signaling activation, including PKC, PI3K/AKT/mTOR, SRC, STAT and RAS/RAF/MEK1/ERK1/2, and regulate numerous EGFR-interacting proteins \[[@B30-ijms-17-01090],[@B31-ijms-17-01090]\]. Recently, one study reported that dysregulation of ubiquitination is a key mechanism of EGFR hyperactivation in PDAC, and low CBL (Casitas B-lineage lymphoma family) may define PDAC tumors likely to respond to erlotinib treatment \[[@B32-ijms-17-01090]\]. Another study identified the lumican/EGFR/AKT/HIF1 α signaling pathway as a mechanism to inhibit pancreatic cancer cell survival and proliferation and prolonged survival after tumor resection, which stressed that lumican plays a restrictive role in EGFR-expressing pancreatic cancer progression \[[@B18-ijms-17-01090]\]. Based on those previous studies, EGFR and the related pathway had shown an important role in pancreatic cancer. Therefore, it is rational to label EGFR as a novel target for treatments of pancreatic cancer.

Adjuvant therapy had shown the survival benefit, but the median OS for patients with resected pancreatic cancer still remains less than 20 months. Multiple trials have been performed to explore other systemic therapies in the adjuvant setting \[[@B33-ijms-17-01090],[@B34-ijms-17-01090],[@B35-ijms-17-01090]\]. In a wide range of human solid carcinomas, molecules involved in EGFR signaling that have aberrant expression were reported as new therapeutic targets \[[@B14-ijms-17-01090]\]. Various therapeutic agents designed to target EGFR and EGFR-associated pathways are currently being developed, including specific antibodies, flavonoid antioxidants, and small molecular EGFR-specific tyrosine kinase inhibitors \[[@B5-ijms-17-01090],[@B36-ijms-17-01090]\]. Preclinical studies of those agents in pancreatic carcinoma have had positive results \[[@B37-ijms-17-01090],[@B38-ijms-17-01090],[@B39-ijms-17-01090]\]. Although gemcitabine is a key adjuvant chemotherapy agent for advanced pancreatic cancer, the combination of agents targeting EGFR and gemcitabine has been shown to be superior to gemcitabine alone \[[@B39-ijms-17-01090],[@B40-ijms-17-01090]\]. Therefore, we hypothesized that EGFR-targeted adjuvant therapy combined with gemcitabine may be a promising therapeutic option in resectable pancreatic cancer patients with positive EGFR expression. It is believed that future clinical trials of EGFR inhibitors should incorporate systematic evaluations of both cytoplasmic and membrane EGFR expression, especially in adjuvant settings.

4. Materials and Methods {#sec4-ijms-17-01090}
========================

4.1. Patients {#sec4dot1-ijms-17-01090}
-------------

We retrospectively evaluated PDAC patients who had been treated at Fudan University Shanghai Cancer Center from 2007 to 2014. A total of 357 patients, 205 males (57%) and 152 females (43%), were histologically diagnosed with ductal adenocarcinoma and underwent surgical R0 resection. R0 resection was defined as absence of macroscopic and microscopic residual tumor \>1 mm from the margin of the resection specimen. Patients with pancreatic endocrine or acinar pancreatic carcinoma were excluded from this study. Written informed consent was obtained from all patients before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Center.

4.2. Adjuvant Therapy {#sec4dot2-ijms-17-01090}
---------------------

In this work, 258 patients accepted chemotherapy and 99 cases did not, and none of the 99 patients accepted any adjuvant therapy including radiotherapy, reasons for which included bad performance status or postoperative complications. The adjuvant chemotherapy regimens included gemcitabine-based (94.4%) and fluoropyrimidine-based (5-FU-based, 5.6%) protocols. In the patients who underwent radiotherapy, the primary tumors and surrounding regions that were thought to affect overall survival were targeted. The study was approved by the ethics committee of Fudan University Shanghai Cancer Center. Written informed consent was obtained from all patients, and the clinical factors were evaluated based on the original histopathology reports and clinical records.

4.3. Tissue Samples {#sec4dot3-ijms-17-01090}
-------------------

Patients with well-defined PDAC were eligible for inclusion if an excised tumor specimen was available for examination of EGFR expression. Ten percent neutral-buffered, formalin-fixed, paraffin-embedded tissue blocks were obtained from surgical resection specimens and cut into 4-μm sections. For pathologic diagnosis, the tissue sections were stained using hematoxylin-eosin. Most of these procedures were performed by the Department of Pathology, Fudan University Shanghai Cancer Center.

4.4. Immunohistochemistry {#sec4dot4-ijms-17-01090}
-------------------------

Immunohistochemical analysis of the formalin-fixed, paraffin-embedded (FFPE) tumor tissues for EGFR expression was performed using the Dako EGFR PharmDx TM kit (Dako, Glostrup, Denmark). The FFPE specimens were evaluated for both cytoplasmic and membranous immunostaining by two independent pathologists blinded to the clinical results (recorded at Fudan University Shanghai Cancer Center). The cases were divided into EGFR-positive and EGFR-negative subgroups based on the intensity and completeness of immunohistochemical staining. The staining intensity was scored as 0 for absent, 1 for weak, 2 for moderate and 3 for strong staining. The staining distribution was scored as 0 (absent) for \<5%, 1 (focal) for 5% to \<50%, and 2 (diffuse) for ≥50% positive-stained areas. The sum of intensity and distribution scores were then used to determine the EGFR immunoreactivity. For membranous or cytoplasmic staining, the intensity score of 1 and 0, or the distribution score of 0, was considered as negative immunoreactivity. Other scores were considered positive immunoreactivity.

4.5. Statistical Analysis {#sec4dot5-ijms-17-01090}
-------------------------

The statistical analysis was performed using SPSS 17.0 statistical software (Chicago, IL, USA). All *p*-values \<0.050 were considered statistically significant. Survival time was defined as the time from radical operation completion to the last contact with the patient or death from the disease. Progression free survival was defined as the time from surgery performed to the first recurrence detected. All the subjects were followed for at least 18 months or until death from the disease. Kaplan--Meier analysis was used to analyze patient survival and calculate survival curves, and the Mantel--Cox log-rank test was used to determine the differences between the curves.

5. Conclusions {#sec5-ijms-17-01090}
==============

In summary, although EGFR status was not able to predict postoperative prognosis based on our data, EGFR expression is strongly correlated with adjuvant treatment outcome. Additional studies are necessary to elucidate the potential mechanisms of the effects of EGFR on tumorigenesis and the significance of EGFR in the treatment of human pancreatic cancer.

We thank Menghong Sun from Tissue Bank, Shanghai Cancer Center for the technical assistance. This work was supported in part by the National Science Foundation of China (Grant Number: 81172276).

Supplementary materials can be found at <http://www.mdpi.com/1422-0067/17/7/1090/s1>.
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Immunohistochemical analysis of EGFR (epidermal growth factor receptor) in PDAC (pancreatic duct adenocarcinoma)tissues. In PDAC tissues, immunoreactivity for EGFR was observed on the surface and in the cytoplasm of cancer cells (**A**--**C**), with no immunoreactivity in the surrounding stroma (**D**). The immunoreactivity was different in respective cases: (**A**) strong; (**B**) moderate; (**C**) weak expression; and (**D**) absent (scale bars, 200 μm).
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![Comparison of overall survival between each EGFR status. Kaplan--Meier Estimates of survival according to EGFR expression (EGFR (+) or EGFR (−)).](ijms-17-01090-g002){#ijms-17-01090-f002}

![Subgroup analysis of adjuvant chemotherapy. Kaplan--Meier estimates of survival of patients who received adjuvant chemotherapy (Chemo) or refused chemotherapy (No chemo) according to EGFR status: EGFR (+) or EGFR (−).](ijms-17-01090-g003){#ijms-17-01090-f003}

![Subgroup analysis of adjuvant radiotherapy. Kaplan--Meier estimates of survival of patients who received adjuvant radiotherapy (Radio) or refused radiotherapy (No radio) according to EGFR status: EGFR (+) or EGFR (−).](ijms-17-01090-g004){#ijms-17-01090-f004}

ijms-17-01090-t001_Table 1

###### 

Characteristics of patients with pancreatic cancer according to EGFR (epidermal growth factor receptor) expression.

  EGFR               Total         Positive vs. Negative                 
  ------------------ ------------- ----------------------- ------------- -------
  Age, years                                                             
  ≤65                231           128                     103           0.685
  \>65               126           67                      59            
  Gender                                                                 
  Male               205           106                     99            0.199
  Female             152           89                      63            
  Tumor location                                                         
  Head               211           117                     94            0.705
  Others             146           78                      68            
  CA 19-9 (U/mL)                                                         
  ≤37                84            49                      35            0.435
  \>37               273           146                     127           
  Size (cm)          3.5 ± 1.6     3.5 ± 1.7               3.5 ± 1.5     0.937
  Differentiation                                                        
  well               7             6                       1             0.015
  moderate           200           119                     81            
  poor               136           61                      75            
  unknown            14            9                       5             
  Tumor stages                                                           
  IA                 24            10                      14            0.473
  IB                 91            54                      37            
  IIA                89            49                      40            
  IIB                153           82                      71            
  Nerve invasion                                                         
  yes                301           169                     132           0.180
  no                 56            26                      30            
  Vessel invasion                                                        
  yes                72            39                      33            0.931
  no                 285           156                     129           
  Lymph metastasis                                                       
  yes                153           82                      71            0.736
  no                 204           113                     91            
  Chemotherapy                                                           
  yes                258           148                     110           0.093
  no                 99            47                      52            
  Radiotherapy                                                           
  yes                68            48                      20            0.003
  no                 289           147                     142           
  Ki67 (%)           34.0 ± 21.6   32.4 ± 20.9             35.8 ± 22.3   0.154

Adjuvant chemotherapy was not associated with EGFR expression (*p* = 0.093), but EGFR expression was significantly correlated with the receipt of radiotherapy (*p* = 0.003).

ijms-17-01090-t002_Table 2

###### 

Hazard ratios (HR) and *p*-value for overall survival (OS) and progression free survival (PFS) associated with conventional prognostic factors and EGFR expression.

  Variables (*n*)    No.   Median PFS (Months)   *p*-Value   Median OS (Months)   Univariate   Multivariate        
  ------------------ ----- --------------------- ----------- -------------------- ------------ -------------- ---- -------
  Age, years                                                                                                       
  ≤65                231   10.5                  0.429       14.7                 1            0.082          \-   \-
  \>65               126   11.4                  13.2        1.25                 \-                               
  Gender                                                                                                           
  Male               205   10.5                  0.205       13.8                 1            0.204          \-   \-
  Female             152   11.8                  14.2        0.85                 \-                               
  Tumor location                                                                                                   
  Head               211   10.8                  0.696       14.0                 1            0.402          \-   \-
  Others             146   11.2                  13.5        0.90                 \-                               
  CA19-9 (U/mL)                                                                                                    
  ≤37                84    12.3                  0.202       17.6                 1            0.039          1    0.026
  \>37               273   10.7                  13.2        1.35                 1.42                             
  Size (cm)                                                                                                        
  ≤3                 178   11.8                  0.172       17.6                 1            0.001          1    0.000
  \>3                179   10.3                  11.0        1.61                 1.67                             
  Differentiation                                                                                                  
  poor               136   10.4                  0.209       14.5                 1            0.015          1    0.000
  moderate           200   11.1                  17.7        0.705                0.716                            
  well               7     19.0                  30.6        0.346                0.385                            
  unknown            14    12.8                  17.7        0.776                0.781                            
  Tumor stages                                                                                                     
  IA                 24    14.4                  0.006       21.0                 1            0.000          1    0.000
  IB                 91    12.1                  19.0        1.56                 1.39                             
  IIA                89    12.1                  17.8        1.73                 1.46                             
  IIB                153   9.27                  14.0        2.66                 2.45                             
  Nerve invasion                                                                                                   
  yes                301   10.7                  0.144       13.8                 1            0.338          \-   \-
  no                 56    12.9                  14.2        0.85                 \-                               
  Vessel invasion                                                                                                  
  yes                72    9.1                   0.092       9.3                  1            0.002          1    0.076
  no                 285   11.3                  15.0        0.63                 0.75                             
  Lymph metastasis                                                                                                 
  no                 153   9.3                   0.001       16.9                 1            0.000          1    0.000
  yes                204   12.4                  10.9        1.71                 1.78                             
  Chemotherapy                                                                                                     
  yes                258   11.6                  0.113       16.1                 1            0.000          1    0.009
  no                 99    9.7                   10.3        1.77                 1.46                             
  Radiotherapy                                                                                                     
  yes                68    13.1                  0.062       23.3                 1            0.001          1    0.006
  no                 289   10.6                  13.1        1.71                 1.70                             
  EGFR                                                                                                             
  Negative           195   12.2                  0.040       15.0                 1            0.574          1    0.986
  Positive           162   9.6                   13.1        1.07                 1.00                             

According to the multivariate analysis, CA19-9, tumor size, lymph node metastasis, and receipt of chemotherapy or radiotherapy were significantly associated with overall survival (detailed information is shown in [Table 2](#ijms-17-01090-t002){ref-type="table"}). Negative vessel invasion was strongly correlated with a favorable outcome in the univariate analysis (HR = 0.63, *p* = 0.002), but this correlation had borderline significance in the multivariate analysis (HR = 0.75, *p* = 0.076).

ijms-17-01090-t003_Table 3

###### 

Hazard ratios (HR) and *p*-value for death associated with demographic and prognostic factors stratified by EGFR expression using univariate and multivariate analyses.

  Characteristics     EGFR (+)   EGFR (−)                                        
  ------------------- ---------- ---------- ------ ------- ------ ------- ------ -------
  Age \> 65           1.30       0.176      \-     \-      1.19   0.318   \-     \-
  Female              0.96       0.820      \-     \-      0.79   0.165   \-     \-
  Head                1.10       0.605      \-     \-      1.11   0.542   \-     \-
  CA19-9 \> 37 U/mL   1.22       0.381      \-     \-      1.55   0.030   1.64   0.016
  Size \> 3 cm        2.36       0.000      2.38   0.000   1.20   0.272   \-     \-
  Nerve invasion      0.69       0.112      \-     \-      2.03   0.012   1.71   0.063
  Vessel invasion     1.28       0.273      \-     \-      1.99   0.000   1.67   0.015
  Lymph metastasis    1.79       0.002      1.97   0.000   1.67   0.002   1.59   0.006
  Chemotherapy        0.47       0.000      0.54   0.002   0.70   0.061   0.80   0.280
  Radiotherapy        0.54       0.055      0.65   0.201   0.60   0.013   0.63   0.029

[^1]: These authors contributed equally to this work.
